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Predictors of Resolution of Hypertension after Adrenalectomy in 
Patients with Aldosterone-producing Adenoma
Primary aldosteronism (PA) is a frequent cause of secondary hypertension and is amenable 
to surgical intervention when it is caused by aldosterone-producing adenoma (APA). Many 
patients, however, continue to require antihypertensive medications to control their blood 
pressure after adrenalectomy. The aim of this study was to determine the preoperative 
factors that predict clinical outcomes after adrenalectomy in patients with APA. We studied 
27 patients (mean age 45±4 yr) who had APA and underwent unilateral adrenalectomy 
between December 1995 and September 2008 at our institution. Clinical and biochemical 
data were evaluated at baseline and after a mean follow-up of 51.8±47.0 months (range, 
6-159). At the end of the follow-up, 16 patients (59.3%) were considered to experience 
“complete resolution” without postoperative medications, whereas 7 patients (25.9%) 
“improved” with medications and 4 patients (14.8%) were “uncontrolled.” Three factors (≤2 
antihypertensive medications [P=0.007], duration of hypertension <6 yr [P=0.002], and 
serum aldosterone <350 pg/mL [P<0.001]) were the predictive for complete resolution in 
univariate analysis. Multivariate regression analysis showed that serum aldosterone level 
(<350 pg/mL) was the single most important factor that predicted complete resolution 
after surgery (P<0.001). The best preoperative clinical factor that predicted resolution of 
postoperative hypertension after adrenalectomy is serum aldosterone level (<350 pg/mL). 
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
Primary aldosteronism (PA) is characterized by the inappropri-
ate excess production of aldosterone, regulated in part indepen-
dently of the renin-angiotensin system. PA is commonly caused 
by aldosterone-producing adenoma (APA) or bilateral adrenal 
hyperplasia, also known as idiopathic hyperaldosteronism (IHA). 
PA causes hypertension, hypokalemia, and alkalosis. PA induced 
by APA is one of the few potentially curable causes of hyperten-
sion and affects 1.4% to 10% of hypertensive patients (1-5).
 Adrenalectomy for APA is the ideal treatment to relieve hypo-
kalemia and improve blood pressure control. Although hypo-
kalemia resolves in more than 98% of patients after adrenalec-
tomy for an APA, hypertension resolves completely in only 20% 
to 35% without further hypertension medications (6-10). This 
condition is called resistant hypertension, of which exact cause 
is unknown.
 Recently, studies have suggested that resistant hypertension 
is associated with dysregulation of the cardiovascular system in 
APA (11-14). Mechanisms of disease pathology include chroni-
cally high levels of aldosterone—which causes chronic intravas-
cular fluid retention—arterial stiffness, suppression of endothe-
lial function, induction of target organ inflammation, and fibro-
sis (15). The benefits of adrenalectomy on APA of the adrenal 
gland in hypertension resolution, however, are debated. 
 The aim of this paper was to investigate the clinical behaviors 
and treatment outcomes in APA after adrenalectomy and to 
identify the preoperative clinical predictors that influence the 
outcomes of hypertension.
MATERIALS AND METHODS
This study is a retrospective case series of patients who under-
went surgical intervention for APA at Ajou University Hospital 
from December 1995 to September 2008. Thirty-eight patients 
with PA entered into the database. Due to missing data or in-
consistencies regarding the diagnosis and lack of surgical inter-
vention, 11 patients were initially excluded from further analy-
sis. The remaining 27 PA patients were correlated with this study 
subjects. We received IRB approval and the recognition number 
is AJIRB-MED-MDB-09-217. 
 Extensive clinical data were extracted from patients’ charts, 
including laboratory test results, dynamic testing, medication, 
adrenal imaging, details of specific medical treatment, and sur-
gical treatment. We checked blood pressure at admission, post-
operatively, and during the follow-up, and we examined the pre-
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operative clinical variables that associated most strongly with 
resolution of hypertension postoperatively to design a multivar-
iate predictive model.
 The following baseline variables were obtained through a re-
view of medical records: age, body mass index (BMI), tumor size, 
family history of hypertension, number of antihypertensive med-
ications, and duration of hypertension. Family history of hyper-
tension was defined as having one or more first-degree family 
members with documented hypertension. The laboratory data 
that were collected included blood levels of potassium and al-
dosterone, plasma renin activity, and aldosterone-to-plasma 
renin activity ratios. 
 We assessed the degree of improvement in hypertension af-
ter adrenalectomy and the clinical outcome data, which con-
sisted of systolic blood pressure (SBP), diastolic pressure (DBP) 
and the number of antihypertensive medications at the postop-
erative visit. We categorized patients into 3 groups; clinically 
cured, improved control, and resistance groups. Patients were 
labeled as clinically cured if they had no hypertension, defined 
as SBP <140 mmHg and DBP M <90 mmHg, and were not tak-
ing any antihypertensive medications after surgery.
 Patients were categorized as having improved control of their 
blood pressure if they were normotensive and required an equal 
number of or fewer antihypertensives postoperatively, or were 
hypertensive and required fewer antihypertensives.
 Subjects were placed into the resistant hypertension group if 
either of 2 criteria were met 6 months postoperatively; persistent 
hypertension (defined as SBP ≥140 mmHg or DBP ≥90 mmHg), 
and continued need of antihypertensive medications to control 
blood pressure adequately. We also compared preoperative clin-
ical factors between groups to predict postoperative hyperten-
sion resolution outcomes according to these criteria. The mean 
follow-up period was 51.8±47.0 months. 
 In the univariate analyses, we compared each of these vari-
ables using t-tests, chi-square tests, and ANOVA, when appro-
priate. To obtain a simple and practical model, continuous vari-
ables were dichotomized using rounded, whole-number values 
that allowed effective discrimination between the groups. We 
selected these cutoffs by identifying predictor variable values 
on a receiver operating characteristic (ROC) curve. After the 
univariate analysis, a multivariate logistic regression model of 
patient characteristics and outcomes was performed to identify 
the clinical variables that were associated with complete resolu-
tion. We recognized the results, when P value is less than 0.01. 
RESULTS
From December 1995 to September 2008, 27 patients underwent 
surgery for adenoma-induced primary aldosteronism. The mean 
age of the patients was 45.3±4.0 yr, and the male-to-female ratio 
was 1:2. The chief symptoms that were used to establish the di-
agnosis of PA included a history of persistent hypertension (85.1 
%), hypokalemic alkalosis (92.5%), muscle weakness (25.9%), 
paresthesia (7.4%), and paralysis (11.1%). Five patients (18.5%) 
had a family history of hypertension. Seventeen patients under-
went laparoscopic surgery, and 10 patients underwent open 
surgery. Eighteen patients had the lesion on the right side, and 
9 had it on the left. There were no serious postoperative compli-
cations.
 The mean duration of hypertension was 67.5±94.0 months 
(range 2.0-408.0 months), and the mean number of antihyper-
tensive medications was 2.3±1.0 (range 1-6). The most common-
ly used antihypertensive medications were beta-blockers, alpha-
blockers, calcium channel blockers, and angiotensin-converting 
enzyme inhibitors. Mean body mass index was 23.8±3.0 kg/m2 
(range 16.6-28.8 kg/m2), mean preoperative serum aldosterone 
level was 124.3±36.0 pg/mL (range 66.0-1,915.0 pg/mL), and 
mean serum renin was 0.5±0.8 ng/mL (range 0.1-4.0 pg/mL). 
The mean aldosterone-renin ratio was 252.2±28.0 (range 7.9-
4,905.0). All patients had diagnosed adenomas, and the mean 
tumor size was 2.2±1.0 cm (range 1.0-5.0 cm). Mean preopera-
tive blood pressure was 162.8±12.0/99.4±18.0 mmHg (range 123-
200/124-53 mmHg), and mean potassium level was 2.5±0.6 mM 
(range 1.5-4.3 mM).
 Hypokalemia was resolved after adrenalectomy in all patients 
at postoperative Week 1, wherein the mean was 4.1±0.5 mM 
(range 3.0-5.7 mM). Hypertension was completely resolved only 
in 16 patients (59.2%) postoperatively, however; the mean blood 
Table 1. Univariate analysis of clinical outcome according to candidate predictor 
variables 
Variables
Resolved  
(Clinical cure, 
n=16)
Not resolved 
(Improved control 
and Resistance, 
n=11)
P
Age (yr) (range) 45.0±5.0 
(27.0-51.0)
43.0±10.0 
(31.0-43.0)
0.105
Sex (M/F) 5/11  
(31.2/68.8%)
4/7  
(36.4/63.6%)
0.597
Body mass index (kg/m2) 23.1±3.2 
(16.6-28.2)
24.7±2.9 
(19.7-28.8)
0.812
Family history of hypertension 25% 9.1% 0.987
Duration of hypertension (months)
46.4±99.0
(2-408)
98.1±82.2
(2-276)
0.002
Number of antihypertensive 
   medications (preop.)
2.0±1.0
(1.0-4.0)
2.7±1.5 <0.001
Tumor size (cm) 1.83±8.0 
(1.0-3.3)
2.6±1.3 
(1.0-5.0)
0.240
Initial laboratory findings
   Potassium (mM) 2.52±0.7 
(1.6-4.3)
2.4±0.6 
(1.7-3.0)
0.814
   Aldosterone (pg/mL) 91.4±21.3 
(66.0-890)
135.8±21.7 
(117.0-1,915.0)
<0.001
   Renin (ng/dL) 0.3±0.4 
(0.02-1.8)
0.6±1.1
(0.2-4.0)
0.042
Aldosterone-renin ratio 173.6±31.4 
(7.9-1,705.0)
297.75±49.0 
(198-4,905.5)
0.742
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pressure was 130.5±12.0/82.8±11.0 mmHg (range 107-154/66-
105 mmHg). The duration of resolution was 5.7±4.0 months 
(range 1.0-5.0 months). According to our category criteria, 16 
(59.2%) were in clinically cured group, 7 (25.9%) had improved 
control, and 4 (14.8%) experienced an ongoing need for medi-
cations and had worse blood pressure control (resistance group). 
The mean number of postoperative antihypertensive medica-
tions was 1.0±0.5. 
 In this study, age, gender, BMI, tumor size, and preoperative 
serum potassium and renin levels were not significantly associ-
ated with complete resolution. In contrast, other variables that 
were significantly associated with complete resolution of hyper-
tension included antihypertensive medications, duration of hy-
pertension, and plasma aldosterone concentrations (Table 1). 
When the proper cutoffs for variables were selected by analyzing 
the ROC curve for each variable, the number of antihypertensive 
medications (≤2), duration of hypertension (≤6 yr), and plasma 
aldosterone levels (≤350 pg/mL) were included in the multivar-
iate analysis. On multivariate analysis, serum aldosterone level 
(≤350 pg/mL) was the only predictor that correlated with com-
plete resolution of hypertension (P<0.001) (Table 2, Fig. 1).
DISCUSSION
As first described by Conn in 1955, PA was thought to be an atyp-
ical cause of hypertension (16), which had a prevalence of <1% 
among general hypertensive patients (16, 17). Recent studies 
indicate, however, that PA is much more common than origi-
nally reported and have estimated prevalence more than 10% 
of the general hypertensive population (18) and approximately 
20% of patients with severe or persistent hypertension (5,14). 
PA is caused by APA in 30% to 60% of cases (9, 21), occurs more 
frequently in women than in men, and occurs rarely in children 
(22). We observed a male-to-female ratio of 1:2, consistent with 
the previous studies.
 The clinical features of APA are nonspecific. Some patients 
are asymptomatic or have minimal symptoms. Here, the clini-
cal manifestations of APA included hypertension, hypokalemic 
alkalosis, renal dysfunction, nephrogenic diabetes insipidus, 
muscle weakness, paresthesia, tetany, and paralysis (5, 14-17). 
In our study, the most common clinical manifestation that was 
used to establish a diagnosis of PA was a history of persistent 
hypokalemic alkalosis (92.5%). Hypertension (85.1%), muscle 
weakness (25.9%), paresthesia (7.4%), and paralysis (11.1%) also 
were found.
 Adrenalectomy typically is chosen to resolve hypokalemia 
and improve blood pressure control in APA patients. Many re-
searchers have suggested that hypokalemia is corrected in more 
than 90% of patients with APA postoperatively (6-10).
 Resistant hypertension, however, defined as blood pressure 
that remains elevated despite antihypertensive agent use, is fre-
quently observed. Although studies have noted the prevalence 
of resistant hypertension after adrenalectomy, the estimates of 
its prevalence vary widely, from 9% to 65% (6, 8, 9, 13, 17, 20). 
This pattern is due to the fact that most studies have been per-
formed retrospectively in a selected cohort of patients and have 
used heterogeneous criteria for selecting patients. In our study, 
complete resolution of hypertension was observed in 59.2% of 
patients, and control of hypertension improved in 25.9% of pa-
tients. Resistant hypertension was found in only 14.8% of sub-
jects.
 Some authors have opined that the mechanism that induces 
resistant hypertension relies on multiple reactions after long-
term aldosterone excess in cardiovascular and renovascular 
system (11-14, 23). They also suggested that high level of aldo-
sterone impairs vascular function by suppression of nitric oxide 
formation and increases in reactive oxygen species. Others have 
shown that inappropriate high aldosterone levels with regard to 
sodium status cause extensive renal damage (24, 25). Aldoste-
rone excess is also associated with glomerular hyperfiltration 
and declines in glomerular filtration rate (24, 25). A recent study 
has emphasized chronic intravascular fluid retention, arterial 
stiffness, suppression of endothelial function, and induction of 
target organ inflammation and fibrosis in resistant hyperten-
sion (15). The underlying cause of resistant hypertension, how-
ever, is controversial.
 The clinical factors that predict the resolution of hypertension 
in APA after adrenalectomy have been investigated and evalu-
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Fig. 1. Rationale for the selection of 350 pg/mL as the cutoff for the plasma serum 
aldosterone level. 
Plasma	aldosterone	levels	
(<350	pg/mL)	
Table 2. Results of multivariate logistic regression analysis of the 3 major predictors
Variables Odds ratio 95% CI P
Years of hypertension <6 yr 10.139   0.326-18.254 0.187
No. of antihypertensive medication ≤2   7.867 0.878-9.721 0.082
Aldosterone <350 pg/mL   6.217 1.020-5.592 0.003
Kim RM, et al. • Predictors of Hypertension Resolution after Adrenalectomy
DOI: 10.3346/jkms.2010.25.7.10411044  http://jkms.org
ated often, but the precise factors remain unknown. Other stud-
ies have presented results that have differed from ours, suggest-
ing that younger age, smaller tumor, lower urinary aldosterone-
renin ratio, lower BMI, and lack of family history of hyperten-
sion are predictors of resolution of hypertension after adrenal-
ectomy (8, 15, 25, 26).
 A recent study that used aldosterone resolution score (ARS) to 
determine score found female gender, use of ≤2 antihyperten-
sive medications, BMI <25, and <6 yr of hypertension to be good 
predictors (6). In our study, plasma aldosterone levels (<350 pg/ 
mL), duration of hypertension (<6 yr), and number of antihy-
pertensives (≤2) were adequate predictors of surgical curability 
of APA, based on our univariate analysis. In our multivariate 
analysis, however, plasma aldosterone level was the only true 
useful predictor of adrenalectomy; plasma aldosterone level 
(<350 pg/mL) was the most accurate independent predictor of 
the effectiveness of surgery. 
 Although the retrospective nature of our study has limitations, 
and although the mechanism of resistant hypertension is un-
clear, these predictors can help clinicians provide objective in-
formation about treatment outcomes to patients with APA be-
fore they undergo surgical intervention. In the future, if we ob-
tain data on more patients and perform the study prospectively, 
we can determine the exact mechanism of resistant hyperten-
sion and identify more accurate predictors. 
 In conclusion, our study shows that 59.2% of patients experi-
enced complete resolution of hypertension and that control of 
hypertension improved in 25.9% of patients. Resistant hyperten-
sion occurred in 14.8% of patients. The best preoperative clini-
cal factor that predicted postoperative hypertension resolution 
after adrenalectomy is serum aldosterone level (<350 pg/mL). 
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